Free Trial
NASDAQ:HCWB

HCW Biologics 8/11/2023 Earnings Report

HCW Biologics logo
$4.26 0.00 (0.00%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$4.14 -0.12 (-2.82%)
As of 07/25/2025 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCW Biologics EPS Results

Actual EPS
-$4.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

HCW Biologics Revenue Results

Actual Revenue
$0.62 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HCW Biologics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

HCW Biologics' next earnings date is estimated for Wednesday, August 13, 2025, based on past reporting schedules.

Conference Call Resources

HCW Biologics Earnings Headlines

HCW Biologics Inc News (HCWB) - Investing.com
Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More HCW Biologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HCW Biologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HCW Biologics and other key companies, straight to your email.

About HCW Biologics

HCW Biologics (NASDAQ:HCWB), a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

View HCW Biologics Profile

More Earnings Resources from MarketBeat